Trials / Completed
CompletedNCT04040309
PRGF Effectiveness for Myofascial Pain Treatment in Masticatory Muscles
Plasma Rich in Growth Factors Effectiveness for Myofascial Pain Treatment in Masticatory Muscles: a Randomized Controlled Clinical Trial
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 50 (actual)
- Sponsor
- Lithuanian University of Health Sciences · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
The investigators set up a randomized controlled clinical trial to evaluate the effectiveness of plasma rich in growth factors (PRGF) injections into the masseter muscle trigger points for myofascial pain treatment. The investigators also seek to compare PRGF injections effectiveness with local anesthetic injections. Dry needling and local anesthetics injections release trigger point by disrupting the membranes of a tout band. However, the injected substance itself does not affect the pathophysiological mechanism of the trigger point. It is known that the platelets release growth factors who can enhance muscle regeneration processes and moreover reduce chronic pain. The investigators raised a hypothesis that PRGF injections into the trigger points in masseter muscle can be an effective treatment method for the myofascial pain.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | PRGF injection | Plasma rich in growth factors will be prepared following the protocol described by E. Anitua. 9 ml of patients venous blood will be taken into one tube with 3,8% sodium citrate used as an anticoagulant. The blood then will be centrifuged (PRGF Centrifuge System, Biotechnology Institute, Vitoria, Spain) at room temperature for 8 min at 1800 rpm. After centrifugation 1 ml of 2nd plasma fraction will be collected by using a pipet. To activate plasma 10% calcium chloride will be used immediately before injecting plasma into the trigger point in the masseter muscle. |
| DRUG | Lidocaine injection | 1 ml 2 % Lidocaine will be injected into the trigger point in the patient's masseter muscle. |
Timeline
- Start date
- 2019-05-10
- Primary completion
- 2019-08-20
- Completion
- 2019-08-25
- First posted
- 2019-07-31
- Last updated
- 2020-02-19
Locations
1 site across 1 country: Lithuania
Source: ClinicalTrials.gov record NCT04040309. Inclusion in this directory is not an endorsement.